ESMO 2019 — Half of melanoma patients in pivotal nivolumab+ipilimumab trial are still alive after 5 years


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • After a minimum follow-up of 5 years, more than 50% of patients with advanced melanoma who received a combination therapy of nivolumab (NIVO) and ipilimumab (IPI) were still alive.

Why this matters

  • This 5-year analysis of CheckMate 067 represents the longest phase 3 follow-up for any checkpoint inhibitor combination therapy.
  • Impressive improvements in PFS and OS were seen with NIVO+IPI in patients with advanced treatment-naïve melanoma. Duration of these benefits is unknown.

Study design

  • 945 patients randomised to NIVO+IPI, NIVO, or IPI.
  • Minimum follow-up now 60 months.
  • Funding: Bristol-Myers Squibb.

Key results

  • The median duration of response and median OS have not been reached under NIVO+IPI.
  • 5-year PFS is 36%, 5-year OS is 52%.
  • There were no large differences in the benefits between patients with or without BRAF mutations or between those with lower (

Expert commentary

  • “With this long follow-up, we can now say with a degree of certainty that PD-1 based therapy is an option for patients with advanced melanoma regardless of PD-L1 status and BRAF mutation,” said Teresa Amaral, Centre for Dermato-oncology, Eberhard Karls University Tübingen, Germany, who was not involved in the study.